InnoSIGN Company Profile

Background

InnoSIGN is a precision medicine company specializing in mRNA-based pathway activity profiling technology. The company aims to revolutionize precision medicine by providing deeper insights into disease mechanisms, thereby guiding therapeutic decisions and improving patient outcomes. InnoSIGN's proprietary platform, OncoSIGNal, analyzes the functional activities of cellular pathways to identify the true drivers of diseases, particularly in oncology.

Key Strategic Focus

InnoSIGN's strategic focus centers on advancing precision medicine through its OncoSIGNal platform. The company specializes in quantifying cell signaling pathway activities, which are crucial for understanding complex and dynamic diseases like cancer. By translating mRNA levels from target genes into pathway activity scores, InnoSIGN provides actionable insights that support drug development, patient stratification for clinical trials, and cancer research. The primary markets targeted include pharmaceutical companies, clinical research organizations, and healthcare providers seeking to enhance treatment selection and patient outcomes.

Financials and Funding

In March 2022, InnoSIGN completed a spin-out from Royal Philips, securing an $8 million Series A financing round. Investors included Casdin Capital, Life Science Angels, Thuja Capital, and Brabant Development Agency, with Philips retaining a minority stake in the new company. In July 2022, an additional $1.2 million was raised during a second closing of the Series A round, bringing the total funds raised to $9.2 million. These funds are intended to support further clinical validation studies and the commercialization of InnoSIGN's OncoSIGNal tests.

Pipeline Development

InnoSIGN's OncoSIGNal platform is designed to analyze the activity of key transcription factors, providing insights into the functional activity of cellular signaling pathways. The platform currently assesses pathways such as ER, AR, PI3K, MAPK, Hedgehog, TGFß, Notch, Wnt, NF-kB, and JAK-STAT1/2. Algorithms for other relevant pathways targeted by drugs are in development. The company offers OncoSIGNal as a lab-developed test for clinical use in breast cancer through its CLIA laboratory in Mason, Ohio, and as a research-use-only test through its laboratory in Eindhoven, Netherlands. Additionally, PCR kits manufactured under ISO13485 and cloud-based algorithms for RNA quality control and pathway interrogation are available.

Technological Platform and Innovation

InnoSIGN's OncoSIGNal platform is distinguished by its proprietary supervised machine learning algorithms, developed over ten years of research at Philips. These algorithms analyze mRNA levels transcribed from direct target genes regulated by pathway transcription factors, translating them into pathway activity scores. This approach captures the complexity of millions of possible signaling events, providing a comprehensive view of disease mechanisms. The platform's extensive database includes over 100,000 pathway activity profiles, supporting diagnostics and drug development by predicting patient responses to targeted therapies.

Leadership Team

Eric Lindquist: Chief Executive Officer

Paul Van de Wiel: Co-Founder & Chief Operating Officer

Anke Pierik, Ph.D.: Chief Technology Officer

Eveline Biezen: Chief Scientific Officer

Sigi Neerken: Co-Founder & Chief Business Officer

In March 2024, Eric Lindquist was appointed as the new Chief Executive Officer, succeeding Paul Van de Wiel, who transitioned to the role of Chief Operating Officer.

Competitor Profile

Market Insights and Dynamics

The precision medicine market is experiencing significant growth, driven by advancements in genomics, bioinformatics, and personalized healthcare. The increasing demand for targeted therapies and the need for comprehensive disease analysis are key factors propelling this expansion.

Competitor Analysis

InnoSIGN operates in a competitive landscape with several key players:

RiboPro: A venture capital-backed company based in Oss, Netherlands, specializing in mRNA technologies.

Qiagen: A former VC-backed company headquartered in Hilden, Germany, offering a range of molecular diagnostics and bioinformatics solutions.

These competitors focus on various aspects of molecular diagnostics and bioinformatics, contributing to the dynamic and evolving nature of the precision medicine industry.

Strategic Collaborations and Partnerships

InnoSIGN has engaged in significant collaborations to enhance its market position and innovation capacity. In March 2024, the company announced a collaboration with NYU Langone Health in breast cancer research. Additionally, in April 2025, InnoSIGN partnered with Scipher Medicine to advance precision medicine in immunology.

Operational Insights

InnoSIGN's strategic considerations include leveraging its proprietary OncoSIGNal platform to differentiate itself from competitors. The company's focus on analyzing functional activities of cellular pathways provides a unique approach to understanding complex diseases, offering distinct competitive advantages in the precision medicine market.

Strategic Opportunities and Future Directions

InnoSIGN's strategic roadmap includes expanding the application of its OncoSIGNal platform across various therapeutic areas beyond oncology, such as autoimmune and infectious diseases. The company aims to enhance its database of pathway activity profiles and develop additional algorithms for other relevant pathways targeted by drugs. By building on its current strengths, InnoSIGN is positioned to achieve future objectives in advancing precision medicine.